OncoMatch/Clinical Trials/NCT05864196

Two Fraction Prostate SBRT With DIL SIB

Is NCT05864196 recruiting? Yes, currently enrolling (May 2026). This Phase 1 trial studies non-drug interventions for prostate cancer.

Phase 1RecruitingNYU Langone HealthNCT05864196Data as of May 2026

Phase I/Ib, single arm trial of Two-Fraction Stereotactic Body Radiation Therapy (SBRT) with an MRI directed, dominant intraprostatic lesion (DIL), simultaneous integrated boost (SIB) based on genomic classification in the treatment of localized prostate cancer. The primary purpose of this study is to determine the feasibility and safety of two fraction SBRT in patients with localized prostate cancer.

Check if I qualify

Extracted eligibility criteria

Cancer type

Prostate Cancer

Disease stage

Required: Stage TX, T2C (8th edition)

Grade: Grade group 1Grade group 2Grade group 3 (NCCN)

Low to intermediate risk National Comprehensive Cancer Network (NCCN) disease * TX-T2c-8th addition staging * PSA<20 ng/ml * Grade group 3 or less

Prior therapy

Cannot have received: radiation therapy

Cannot have received: prostate surgery

Structured fields extracted by AI. May contain errors — verify against the official protocol.

US trial sites

NYU Langone Hospital - Long Island · Mineola, New York
NYCyberKnife at Perlmutter Cancer Center · New York, New York

Showing up to 5 US sites. See all sites on ClinicalTrials.gov →

Could you qualify for this trial?

Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.

Check if I qualify